NCT04619706终止2 期
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIA Study of FSD201 (Ultramicronized PEA) + Standard of Care (SOC) Vs SOC in the Treatment of Hospitalized Patients With COVID-19
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 53
- 试验地点
- 10
- 主要终点
- Percentage of Participants With Disease Progression at Day 28
研究概览
简要总结
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must be willing and able to give informed consent to participate in the study
- •Has admitted to a hospital and has a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test by standard reverse transcription-polymerase chain reaction (RT-PCR) assay or equivalent test
- •Has the presence of any symptom(s) suggestive of moderate or severe systemic illness with COVID-19 on Day 1 such as the presence of fever (greater than or equal to (>=)38.0 degree Celsius [>=100.4 degree fahrenheit] by any route), "feeling hot," "feeling sweaty," headache, malaise, fatigue, muscle pain, diarrhea, nausea, vomiting, cough, sore throat, or shortness of breath upon exertion and/or at rest, or respiratory distress
- •Has the presence of moderate to severe clinical signs indicative of moderate or severe illness with COVID-19 on Day
- •A. Moderate: (1) Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate >=20 breaths per minute, SpO2 >93% on room air at sea level, heart rate >=90 beats per minute. (2) No clinical signs indicative of severe or critical COVID-
- •B. Severe: (1) Clinical signs suggestive of severe systemic illness with COVID-19, such as respiratory rate >=30 breaths per minute, heart rate >=125 beats per minute, SpO2 less than or equal to (<=) 93% on room air at sea level or partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) less than (<)300, heart rate >=125 beats per minute. (2) No criteria met for critical COVID-19
- •Has either normal renal function or mild or moderate renal impairment: estimated creatinine clearance >30 milliliters per minute (mL/min) on Day 1
- •Able to swallow the study drug (tablets)
- •Men whose sexual partners are women of childbearing potential (WOCBP) must agree to comply with one of the following contraception requirements from the time of first dose of study medication (Day 1) until at least 30 days after the last dose of study medication: (a) Vasectomy with documentation of azoospermia. (b) Sexual abstinence. (c) Male condom plus partner use of one of the contraceptive
- •WOCBP must agree to comply with one of the following contraception requirements from the time of first dose of study medication (Day 1) until at least 30 days after the last dose of study medication: (a) Sexual abstinence (b) Use of one of the contraceptive options (c) Vasectomy of male partner with documentation of azoospermia
排除标准
- •The participant, in the opinion of the investigator, is not likely to survive for >=48 hours beyond Day 1
- •Has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19 on Day 1
- •Has a documented current liver disease, or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones) at screening or on Day 1
- •Has a Child Pugh score >= C
- •Has a documented medical history of infection with human immunodeficiency virus or hepatitis A, B, or C at screening or on Day 1
- •Has a documented active infection with tuberculosis at screening or on Day 1
- •Has clinically significant ECG abnormalities at screening or on Day 1
- •Requires dialysis or is on any renal replacement therapies at screening or on Day 1
- •A female participant who is pregnant or planning to become pregnant during the study, breastfeeding, or has a positive pregnancy test at screening
- •Receiving alpha-blockers, combined alpha/beta blockers, antihistamines, or any drugs that will affect the levels of cytokines released due to immune stress
- •Has received any immunoglobulins within 6 months of screening or planned administration of any immunoglobulins during the screening and/or treatment periods
- •Has a known history of drug abuse within 6 months of study start that would interfere with the participant's participation in the study
- •Has a history of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, would contraindicate their participation
- •Has participated in and/or plan to participate in another clinical study
- •Will be transferred to another hospital which is not a study site within 72 hours
- •Cannot read and speak either English or Spanish
- •Other protocol defined Inclusion/Exclusion criteria may apply
研究组 & 干预措施
Arm A: FSD201 600 mg
Experimental
Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
干预措施: FSD201 (Drug)
Arm A: FSD201 600 mg
Experimental
Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
干预措施: Placebo (Drug)
Arm A: FSD201 600 mg
Experimental
Participants will receive 600 milligrams (mg) FSD201 tablet twice daily (BID) orally along with the placebo matched to 600 mg FSD201 tablet from Day 1 to Day 14.
干预措施: Standard of Care for Covid-19 (Other)
Arm B: FSD201 1200 mg
Experimental
Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
干预措施: FSD201 (Drug)
Arm B: FSD201 1200 mg
Experimental
Participants will receive 1200 mg (2x600 mg) tablets FSD201 BID orally from Day 1 to Day 14.
干预措施: Standard of Care for Covid-19 (Other)
Arm C: Placebo
Placebo Comparator
Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
干预措施: Placebo (Drug)
Arm C: Placebo
Placebo Comparator
Participants will receive placebo matched to 600 mg FSD201 tablets (2xplacebo tablets) from Day 1 to Day 14.
干预措施: Standard of Care for Covid-19 (Other)
结局指标
主要结局
Percentage of Participants With Disease Progression at Day 28
时间窗: Day 28
Disease progression will be defined as the percentage of participants who are not alive or who have respiratory failure. Respiratory failure will be defined as the need for invasive or non-invasive mechanical ventilation, high-flow oxygen, or extracorporeal membraneoxygenation (ECMO).
次要结局
- Percentage of Participants With Disease Resolution at Day 28(Day 28)
- Percentage of Participants Testing Negative for COVID-19 at Day 28(Day 28)
- Plasma Concentrations of FSD201(Day 1 and Day 14)
- Maximum Observed Plasma Concentration (Cmax) of FSD201(Day 1 and Day 14)
- Percentage of Participants Requiring Invasive Mechanical Ventilation or ExtraCorporeal Membrane Oxygenation (ECMO) or who are not Alive on Day 28(Day 28)
- Change From Baseline in Oxygen use(Baseline, Day 15, and Day 28)
- Change From Baseline in Saturation of Oxygen (SpO2) percent (%)(Baseline through Day 28)
- Change From Baseline in Clinical Status Related to COVID-19(Baseline, Day 15, and Day 28)
- Percentage of Participants who Die (Mortality Rate) at Day 28(Day 28)
- Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)(From the signing of the informed consent to Day 60 (approximately 9 months))
- Area Under the Concentration-Time Curve (AUC) of FSD201(Day 1 and Day 14)
- Number of Participants With Clinically Significant Changes in Vital Signs, Laboratory Parameters, Electrocardiogram Findings and Physical Examination Findings(Baseline through Day 28)
- Elimination Half-Life (t1/2)(Day 1 and Day 14)
- Apparent Total Body Clearance (CL/F) of FSD201(Day 1 and Day 14)
- Apparent Volume of Distribution (Vz/F) of FSD201(Day 1 and Day 14)
- Average Observed Plasma Concentration at Steady State (Cav) of FSD201(Day 1 and Day 14)
研究者
研究点 (10)
Loading locations...
相似试验
终止
2 期
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)Mast Cell Activation SyndromeMast Cell Activation Disorder IdiopathicNCT05652907Quantum Biopharma2
已完成
2 期
PSD502 in Subjects With Premature EjaculationPremature EjaculationNCT03578783Plethora Solutions Ltd121
已完成
2 期
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's DiseaseAlzheimer's DiseaseNCT01374438Metabolic Solutions Development Company29
终止
1 期
Safety, Tolerability and Pharmacodynamics of SYNB1020CirrhosisNCT03447730Synlogic23
Enrolling By Invitation
1 期
A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202Healthy SubjectsNCT06564467Shanghai JMT-Bio Inc.54